Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)

#2182

Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.

Aim(s): We assessed PRRT outcomes in pts with somatostatin receptor (SSTR) positive metastatic rectal NEN from 2 referral centres.

Materials and methods: Pts treated with PRRT were retrospectively reviewed. Anatomical imaging (RECIST 1.1), SSTR imaging response and toxicity were assessed 3 months post-PRRT. Kaplan-Meier estimate was used to determine progression free survival (PFS) and overall survival (OS) from start of PRRT.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kong G

Authors: Kong G, Grozinsky-Glasberg S, Akhurst T, Hofman M, Meirovitz A,

Keywords: PRRT, Lu-177, metastatic, Rectal, Neuroendocrine neoplasm,